Nutex Health (NASDAQ:NUTX) Given New $225.00 Price Target at Maxim Group

Nutex Health (NASDAQ:NUTX) had its target price upped by Maxim Group from $100.00 to $225.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Benchmark upped their target price on shares of Nutex Health from $150.00 to $300.00 and gave the stock a “buy” rating in a research note on Thursday, May 15th.

Nutex Health Stock Performance

NASDAQ NUTX opened at $177.21 on Tuesday. Nutex Health has a 1 year low of $4.16 and a 1 year high of $184.28. The company has a debt-to-equity ratio of 3.36, a current ratio of 1.77 and a quick ratio of 1.74. The firm has a market cap of $986.35 million, a price-to-earnings ratio of -18.88 and a beta of -0.10. The company has a fifty day moving average price of $107.01 and a 200-day moving average price of $63.58.

Nutex Health (NASDAQ:NUTX) last posted its earnings results on Tuesday, May 13th. The company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $2.71. Nutex Health had a negative net margin of 14.09% and a negative return on equity of 51.27%. The firm had revenue of $211.79 million during the quarter, compared to analyst estimates of $81.09 million.

Insider Activity at Nutex Health

In related news, CFO Jon Christian Bates purchased 1,000 shares of Nutex Health stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average price of $81.81 per share, for a total transaction of $81,810.00. Following the completion of the transaction, the chief financial officer now owns 4,888 shares in the company, valued at $399,887.28. This represents a 25.72% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 38.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nutex Health

Several institutional investors have recently added to or reduced their stakes in NUTX. Drive Wealth Management LLC bought a new position in Nutex Health during the fourth quarter valued at about $1,122,000. Baader Bank Aktiengesellschaft bought a new position in Nutex Health during the fourth quarter valued at about $206,000. Legato Capital Management LLC grew its position in Nutex Health by 26.8% during the fourth quarter. Legato Capital Management LLC now owns 31,669 shares of the company’s stock valued at $1,004,000 after buying an additional 6,697 shares during the period. Truist Financial Corp grew its position in Nutex Health by 22.2% during the fourth quarter. Truist Financial Corp now owns 35,570 shares of the company’s stock valued at $1,127,000 after buying an additional 6,454 shares during the period. Finally, Essex Investment Management Co. LLC grew its position in Nutex Health by 45.4% during the fourth quarter. Essex Investment Management Co. LLC now owns 105,809 shares of the company’s stock valued at $3,353,000 after buying an additional 33,024 shares during the period. Institutional investors own 5.32% of the company’s stock.

About Nutex Health

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.